Talampanel: Difference between revisions
Content deleted Content added
Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject_Pha... |
No edit summary |
||
| Line 67: | Line 67: | ||
{{antineoplastic-drug-stub}} |
{{antineoplastic-drug-stub}} |
||
{{anticonvulsant-stub}} |
{{anticonvulsant-stub}} |
||
[[uk:GYKI 53405]] |
|||
Revision as of 23:42, 31 January 2012
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.230.001 |
| Chemical and physical data | |
| Formula | C19H19N3O3 |
| Molar mass | 337.372 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
  (what is this?) (verify) | |
Talampanel (GYKI 53405) is a drug which is being investigated for the treatment of epilepsy,[1] malignant gliomas[2] and amyotrophic lateral sclerosis (ALS).[3].
As of May 2010, results from the trial for ALS have been found negative.[4]
It is a noncompetitive antagonist of the AMPA receptor, a type of glutamate receptor in the central nervous system.[5]
References
- ^ PMID 19443931
- ^ PMID 20143438
- ^ PMID 19961264
- ^ Talampanel Trial, Talampanel Trial on alsa.org
- ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1111/j.1528-1167.2008.01947.x, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with
|doi=10.1111/j.1528-1167.2008.01947.xinstead.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
 | This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |